<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185209</url>
  </required_header>
  <id_info>
    <org_study_id>PERI-IMPL</org_study_id>
    <nct_id>NCT02185209</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics</brief_title>
  <official_title>Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics A Prospective, Double Blind, Randomized, Three Armed, Parallel, Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Margareta Hultin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if the use of systemic adjunctive antibiotics in&#xD;
      the treatment of periimplantitis is needed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will give the opportunity to draw scientifically based conclusions on the&#xD;
      recommendations of the use of adjunctive systemic antibiotics in the treatment of&#xD;
      peri-implantitis. This study will also be able to determine the ecological impact on the&#xD;
      oropharyngeal and intestinal microflora between different antibiotic treatments. The lack of&#xD;
      knowledge in this area has been highlighted by the Food and Drug Administration and The&#xD;
      Swedish Council on Health Technology Assessment (SBU)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probing pocket depth change and bone level stability</measure>
    <time_frame>0,6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of clinical soft tissue inflammation, bleeding on probing (BOP)</measure>
    <time_frame>0, post operative 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soft tissue recession (REC) and clinical attachment level gain (CAL)</measure>
    <time_frame>0,6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Quantitative and qualitative change in levels of the peri-implant periopathogenic microflora</measure>
    <time_frame>0,6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Susceptibility changes of the oral and intestinal microflora to amoxicillin, metronidazole and penicillin.</measure>
    <time_frame>0,6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative and qualitative changes in the oral and intestinal microflora</measure>
    <time_frame>0,6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of amoxicillin, metronidazole and PcV in saliva and feces</measure>
    <time_frame>0, 6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Follow-up of adverse events related or unrelated to the investigated medical products</measure>
    <time_frame>0,6, and 12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Periodontal Diseases</condition>
  <condition>Periimplantitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amoxicillin + metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phenoxymetylpencillin + metronidazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Place capsule to mimic antibiotics</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Sandoz</intervention_name>
    <description>Tablet 500 mg amoxicillin Sandoz three times a day</description>
    <arm_group_label>amoxicillin + metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Sanofi</intervention_name>
    <description>400 mg metronidazole Sanofi administered three times a day (TID)</description>
    <arm_group_label>amoxicillin + metronidazole</arm_group_label>
    <arm_group_label>phenoxymetylpencillin + metronidazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenoxymethylpenicillin Meda</intervention_name>
    <description>1600 mg phenoxymethylpenicillin Meda, three time a day (TID)</description>
    <arm_group_label>phenoxymetylpencillin + metronidazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18-65 year&#xD;
&#xD;
          2. Patients who has been referred by a general dentist to a specialist clinic in&#xD;
             periodontology for treatment of peri-implantitis.&#xD;
&#xD;
          3. Having sign of peri-implantitis around at least one osseointegrated dental implant&#xD;
             that has been in function for ≥ one year&#xD;
&#xD;
          4. Peri-implantitis is diagnosed when; PPD of ≥ 6mm can be found at a dental implant in&#xD;
             association with BOP and/or suppuration together with the loss of marginal alveolar&#xD;
             bone of more than 2 mm detected on intraoral radiographs (giving radiographic exposure&#xD;
             of at least ≥ 3 fixture threads).&#xD;
&#xD;
          5. Partially or completely edentulous subjects with healthy or treated periodontal&#xD;
             conditions enrolled in a regular supportive program.&#xD;
&#xD;
          6. Full-Mouth Plaque Score (FMPS) ≤ 25&#xD;
&#xD;
          7. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to amoxicillin, penicillin (PcV), metronidazole or betalactamic&#xD;
&#xD;
          2. Contraindication for dental surgical treatment (i.e. immunocompromised, uncontrolled&#xD;
             DM (B-GHb-A1C 8-9 %, 64-75 mmol/mol), osteoporosis, I.V bisphosphonate treatment due&#xD;
             to malignancy, pregnant and lactating women).&#xD;
&#xD;
          3. Incapability to perform basal oral hygiene measures due to physical or mental&#xD;
             disorders.&#xD;
&#xD;
          4. Received systemic antimicrobial therapy in the past three months.&#xD;
&#xD;
          5. Currently on allopurinol, digoxin, disulfiram, lithium, busulfan, 5-fluorouracil,&#xD;
             methotrexate, phenytoin, cyclosporine and warfarin.&#xD;
&#xD;
          6. Known severe chronic peripheral or central disease of the nervous system&#xD;
&#xD;
          7. Known alcohol abuse&#xD;
&#xD;
          8. Known hepatic encephalopathy&#xD;
&#xD;
          9. Known lactose intolerance, galactose intolerance&#xD;
&#xD;
         10. Untreated periodontal condition.&#xD;
&#xD;
         11. Implant showing sign of mobility.&#xD;
&#xD;
         12. Implants with bone loss exceeding 2/3 of the length of the implant or implants with&#xD;
             bone loss beyond any transverse openings in hollow implants.&#xD;
&#xD;
         13. Any medical condition or on any concomitant medication that, in the opinion of the&#xD;
             investigator, might interfere with the evaluation of the study objectives or&#xD;
             jeopardize patient safety&#xD;
&#xD;
        Patients with xerostomia or having slow bowel motion will be excluded from the group of&#xD;
        patients providing salivary and fecal samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margareta Hultin, DDSass. prof</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institute, Dental medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bodil Lund, DDSass.prof</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institute, Dental Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalia Kahlil, DDS, PhDstud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, Dental Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margareta Hultin, DDS, ass. prof</last_name>
    <phone>+46 (0)8-524 882 48</phone>
    <email>margareta.hultin@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bodil Lund, DDS prof</last_name>
    <email>bodil.lund@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Folktandvården Skanstull</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Grundström, O.D</last_name>
      <email>Caroline.Grundström@ftv.sll.se</email>
    </contact>
    <investigator>
      <last_name>Caroline Grundström, O.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leif Jansson, O.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Folktandvården Kaniken</name>
      <address>
        <city>Uppsala</city>
        <zip>SE 753 09</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saeed Shamani, O.D</last_name>
      <phone>+46(0)18 611 63 80</phone>
      <email>saeed.shamani@ki.se</email>
    </contact>
    <investigator>
      <last_name>Britt-Marie Herdevall, O.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Margareta Hultin</investigator_full_name>
    <investigator_title>DDS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Penicillin V</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

